- Home
- CROX vs ALKS Comparison
CROX vs ALKS Comparison
Compare CROX & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- ALKS
- Stock Information
- Founded
- CROX 1999
- ALKS 1987
- Country
- CROX United States
- ALKS Ireland
- Employees
- CROX N/A
- ALKS N/A
- Industry
- CROX Shoe Manufacturing
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- CROX Consumer Discretionary
- ALKS Health Care
- Exchange
- CROX Nasdaq
- ALKS Nasdaq
- Market Cap
- CROX 5.7B
- ALKS 5.1B
- IPO Year
- CROX 2006
- ALKS 1991
- Fundamental
- Price
- CROX $103.80
- ALKS $30.28
- Analyst Decision
- CROX Buy
- ALKS Buy
- Analyst Count
- CROX 13
- ALKS 12
- Target Price
- CROX $128.17
- ALKS $40.00
- AVG Volume (30 Days)
- CROX 1.2M
- ALKS 1.9M
- Earning Date
- CROX 08-07-2025
- ALKS 07-23-2025
- Dividend Yield
- CROX N/A
- ALKS N/A
- EPS Growth
- CROX 26.25
- ALKS N/A
- EPS
- CROX 16.31
- ALKS 2.09
- Revenue
- CROX $4,100,808,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- CROX $2.95
- ALKS N/A
- Revenue Next Year
- CROX $2.84
- ALKS $4.25
- P/E Ratio
- CROX $6.36
- ALKS $14.45
- Revenue Growth
- CROX 2.09
- ALKS N/A
- 52 Week Low
- CROX $86.11
- ALKS $22.97
- 52 Week High
- CROX $151.13
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- CROX 49.71
- ALKS 55.80
- Support Level
- CROX $103.90
- ALKS $28.67
- Resistance Level
- CROX $107.90
- ALKS $30.90
- Average True Range (ATR)
- CROX 3.30
- ALKS 0.68
- MACD
- CROX 0.43
- ALKS 0.18
- Stochastic Oscillator
- CROX 58.46
- ALKS 71.78
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.